Viridian Therapeutics, Inc. (VRDN)
31.83
+0.08
(+0.25%)
USD |
NASDAQ |
Jan 12, 12:21
Viridian Therapeutics Research and Development Expense (Quarterly): 86.15M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 2.346M |
| Orthofix Medical, Inc. | 14.77M |
| ADMA Biologics, Inc. | 1.528M |
| Avantor, Inc. | -- |
| Immunovant, Inc. | 114.25M |